Importance: The optimal treatment regimen for myopic choroidal neovascularization (mCNV) is essential to understand but currently poorly studied.
Background: To date, there is still no consensus on the optimal dosage and frequency of anti-vascular endothelial growth factor injections in treating mCNV.
Design: A prospective, single-centre, single-blind, randomized controlled study.
Participants: Adult patients with active mCNV.
Methods: Patients were randomized 1:1 to one or three doses initial ranibizumab treatments. Additional injections were administered pro re nata (prn) over 12 mo.
Main outcome measures: Number and frequency of injections.
Results: Fifty patients participated in the study. Patients in both 1 + prn or 3 + prn groups experienced similar best-corrected visual acuity gain and anatomical improvement, including central retinal thickness (CRT), CNV thickness, area of CNV and area of leakage. Over 12 mo, patients in the 1 + prn group received fewer ranibizumab injections (2.04 ± 1.22) compared with the 3 + prn group (3.58 ± 0.72, P<0.0001), but no statistic difference of the injection received was observed in the prn period. During the follow-up, 15 of 26 eyes in the 1 + prn group and 10 of 24 eyes in the 3 + prn group received additional injections after initial dosing (P = 0.2575). Cox regression analysis showed that 1 + prn, female, age > 55 y and CRT > 300 μm are risk factors for retreatment.
Conclusions and relevance: The eyes with a single loading dose achieved parallel anatomical and functional visual improvement, while required less injections over 1 y. The risk factors for retreatment include 1 + prn, female, older age and thick retina thickness.
Keywords: clinical trial; mCNV; myopic choroidal neovascularization; ranibizumab; treatment.
© 2018 Royal Australian and New Zealand College of Ophthalmologists.